EN DE
Watch Trajan Group Holdings Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Trajan Group Holdings Ltd (TRJ) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Trajan Group Holdings Ltd stock A$0.18, price A$0.32, that is 43.8% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU0000150526

TG Trajan Group Holdings Ltd logo Thin data Nov 17, 2026

Trajan Group Holdings Ltd

TRJ · AU

Far too expensive (fair value 44% below the price) and falling price, but company just good enough: meets 1 of 3 rules.

Get notified free when this changes
Low debt 
Quality 46/100 
Expensive Growth (revenue 5y +16.1 %/yr in AUD) 
Revenue last quarter 10% below a year ago. 
Fair value A$0.1800 · Strongly overvalued 
Falling price (downtrend) 
Loss-making · -0.4% net margin (TTM) 
Negative free cash flow 
Trails peers (3/11) 
Narrow moat 23/100 · thin data
Thin data 
Watch Trajan Group Holdings Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$4.49 A$0.1550 Fair Value A$0.1800 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range A$0.1550 – A$4.49 · fair‑value band A$0.1800 – A$0.2900 · the A$0.3200 price screens above the A$0.1800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Trajan Group Holdings in your weekly email

Every Wednesday you see whether Trajan Group Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Trajan Group Holdings Limited develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.

Show moreShow less

The company offers analytical products, including syringes, GC columns and septa, inlet liners, rings, and tubing products; and sampling products, comprising septa, caps, liners, well plates and sealing mats, crimping tools, and micro sampling tools, as well as automation systems and consumables.

It also provides pathology products, consisting of NBF containers, adhesive and frosted microscope slides, coverslips, microtome blades, biopsy pads, microscope slide storage trays/mailers, microscope slide and cassette storage boxes, histology wax plus, and tissue marking dyes and sets, and MiPlatform, a smartphone adapter; on-line and laboratory instruments and related parts and services; and miniaturized and portable instrumentation, as well as products and services related to microsampling.

In addition, the company offers analytical, automation, life sciences, sampling literature support products. The company was incorporated in 2011 and is headquartered in Ringwood, Australia.

Stock analysis

Trajan Group Holdings Ltd (TRJ) currently trades at A$0.3200, while our model-based Fair Value estimate is A$0.1800, 44% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of A$0.4800 per share, and 2 of the 7 models we run sit above the A$0.3200 price.

Bear case: the Asset-Based group reads lowest at A$0.0800, and 5 of the 7 models stay below the price. Data coverage for this calculation is low.

Scenario range: A$0.1800 (bear) to A$0.2900 (bull), the price of A$0.3200 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Trajan Group Holdings Ltd reported revenue of A$161M in FY2026 versus A$108M in FY2022, a compound +10.7%/yr. Reported net income was −A$623K in FY2026.

Key figures

Market cap A$48.9M (≈ $33.0M) Micro · P/S ratio 0.25 · Net margin −0.4% · Return on equity −0.6% · Return on assets (EBIT) 2.4% (5-year average) · Operating margin 2.6% · Revenue (TTM) A$161M · Revenue growth (YoY) −9.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 55% below its 52-week high and 106% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −44%, TRJ screens richer than that median.

Fair Value models

Bear A$0.1800 Fair Value A$0.1800 Bull A$0.2900
Price A$0.3200 · Downside -43.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV A$0.0700 A$0.1100 A$0.1500 72
ROIC Compounder A$0.0700 A$0.1100 A$0.1500 71
Owner Earnings A$0.1800 A$0.4800 A$1.01 70
All 7 models by family
DCF Models
Owner Earnings A$0.1800 A$0.4800 A$1.01 70
Earnings-Based
EPV A$0.0700 A$0.1100 A$0.1500 72
Multiples
EV/EBIT A$0.0600 A$0.1800 A$0.2900 61
EV/EBITDA A$0.5900 A$0.8900 A$1.19 66
EV/Revenue n/a A$0.0600 A$0.1700 50
Asset-Based
NCAV (Graham) A$0.0600 A$0.0800 A$0.1200 54
Economic Profit
ROIC Compounder A$0.0700 A$0.1100 A$0.1500 71

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 24
How much profit the company makes from its sales and capital
Quality Growth 44
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 40
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 49
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 15
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−3.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.1%
Start year 2021 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.7% (2021) → 2.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

TRJ screens overvalued: fair value 44% below the price. Compare with Intuitive Surgical, Inc →

Compare Trajan Group Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Bottom 25%
Fair Value upside −43.8% · Below median
Profitability
Return on assets −0.3% · Below median
Net margin (12 months) −0.4% · Below median
Operating margin (12 months) 2.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) −9.5% · Bottom 25%
Balance sheet
Debt / equity 0.42× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 0.50× · Cheapest 25%
P/S (12 months) 0.30× · Cheapest 25%
EV/EBITDA 8.4× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 21
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)79 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $88.65 $131.27 +48% vs TRJ
EssilorLuxottica Société anonyme EL €184.50 €196.22 +6% vs TRJ
Intuitive Surgical, Inc ISRG $437.75 $353.90 −19% vs TRJ
Medline Inc MDLN $39.17 $28.59 −27% vs TRJ
Alcon Inc ALC CHF 62.14 CHF 35.08 −44% vs TRJ
Becton, Dickinson and Company BDX $216.47 $97.80 −55% vs TRJ
Straumann Holding STMN CHF 108.75 CHF 45.50 −58% vs TRJ
West Pharmaceutical Services, Inc WST $417.80 $139.22 −67% vs TRJ
Sartorius Stedim Biotech S.A DIM €225.20 €54.82 −76% vs TRJ
Sartorius Aktiengesellschaft SRT €226.50 €46.44 −80% vs TRJ

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Trajan Group Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Trajan Group Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/TRJ

Frequently asked questions

Is Trajan Group Holdings Ltd (TRJ) overvalued or undervalued?
As of Nov 17, 2026, our model estimates a fair value of A$0.1800 versus a price of A$0.3200, about 44% lower (overvalued).
What is the fair value of TRJ?
Our model-based fair value for Trajan Group Holdings Ltd is A$0.1800 (as of Nov 17, 2026), built from audited fundamentals. The current price: A$0.3200.
What is the quality score of TRJ?
Trajan Group Holdings Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Trajan Group Holdings Ltd (TRJ)?
Our model-based price target is the fair value of A$0.1800 (as of Nov 17, 2026) from 7 valuation models. Cautious scenario A$0.1800, optimistic scenario A$0.2900. It is a calculation from audited fundamentals, not an analyst target.
What is the Trajan Group Holdings Ltd stock forecast for 2026?
Our models put fair value at A$0.1800, about 44% lower versus a price of A$0.3200 (overvalued). Cautious scenario A$0.1800, optimistic scenario A$0.2900. The calculation is refreshed regularly with new filings.
What is the revenue of Trajan Group Holdings Ltd (TRJ)?
Trajan Group Holdings Ltd reported trailing-twelve-month revenue of about A$161M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Trajan Group Holdings Ltd (TRJ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Trajan Group Holdings Ltd it is A$0.1800 per share (as of Nov 17, 2026), against a price of A$0.3200. It is the blended result of 7 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit).
Is Trajan Group Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 17, 2026, TRJ trades above its calculated fair value: price A$0.3200, fair value A$0.1800, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TRJ?
No. The price is what the market pays today (A$0.3200); the fair value is what the company's own numbers justify (A$0.1800). For Trajan Group Holdings Ltd the two are A$0.1400 per share apart. That gap is exactly why we show both numbers side by side.
How much is Trajan Group Holdings Ltd worth?
The market values Trajan Group Holdings Ltd at about A$48.9M (market capitalisation, as of Nov 17, 2026). Per share that is A$0.3200; our models calculate a fair value of A$0.1800 per share.
What do the bullish and bearish scenarios say about TRJ?
Our models span a range for Trajan Group Holdings Ltd: cautious scenario A$0.1800, base A$0.1800, optimistic A$0.2900 per share (as of Nov 17, 2026, price A$0.3200). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Trajan Group Holdings Ltd (TRJ)?
Balance-sheet figures for Trajan Group Holdings Ltd (as of Nov 17, 2026): return on equity −0.6%, debt of 0.42 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is TRJ from its 52-week high?
Trajan Group Holdings Ltd trades at A$0.3200, about 55% below its 52-week high of A$0.7100 and 106% above the low of A$0.1550 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.1800 is for.
Which stocks are comparable to Trajan Group Holdings Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Trajan Group Holdings Ltd stock attractive at the current price?
The data as of Nov 17, 2026: price A$0.3200, calculated fair value A$0.1800 (−44%), Quality Score 46/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TRJ calculated?
We run Trajan Group Holdings Ltd through 7 models from 5 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit. Every model gets the same audited fundamentals; the fair value of A$0.1800 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Trajan Group Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Trajan Group Holdings Ltd (TRJ)?
The closing price on Nov 17, 2026 was A$0.3200. Our model-based fair value is A$0.1800, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Trajan Group Holdings Ltd right now?
The price sits above even our optimistic bull case (A$0.2900). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Trajan Group Holdings Ltd

How large is the market capitalisation of Trajan Group Holdings Ltd (TRJ)?
The market capitalisation of Trajan Group Holdings Ltd is A$48.9M (≈ $33.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Trajan Group Holdings Ltd (TRJ)?
The price-to-sales ratio of Trajan Group Holdings Ltd is 0.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Trajan Group Holdings Ltd (TRJ)?
The net margin of Trajan Group Holdings Ltd is −0.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Trajan Group Holdings Ltd (TRJ)?
The return on equity (ROE) of Trajan Group Holdings Ltd is −0.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Trajan Group Holdings Ltd (TRJ)?
On an EBIT basis the return on assets of Trajan Group Holdings Ltd is 2.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Trajan Group Holdings Ltd (TRJ)?
The operating margin of Trajan Group Holdings Ltd is 2.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Trajan Group Holdings Ltd (TRJ)?
Revenue at Trajan Group Holdings Ltd is down 9.5% versus a year earlier (3y avg −0.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Trajan Group Holdings Ltd (TRJ)?
Earnings per share at Trajan Group Holdings Ltd are growing 20.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Trajan Group Holdings Ltd (TRJ) generate?
The free cash flow of Trajan Group Holdings Ltd is −A$3.2M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Trajan Group Holdings Ltd (TRJ) carry?
The net debt of Trajan Group Holdings Ltd is A$45.3M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Trajan Group Holdings Ltd in the live analysis

One click puts Trajan Group Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.